Absci Corp.

Absci Corp. , based in the US, operates an integrated AI Drug Creation Platform focusing on biologics, specifically targeting differentiated antibodies for various medical conditions, including androgenetic alopecia. Absci Corp. was founded in 2011 and is headquartered in Vancouver, US.

The company specializes in AI-driven drug discovery and has engaged in multiple funding rounds, with the most recent being a PIPE round raising USD 20. 00 mn in July 2021, bringing the total amount raised to USD 20. 00 mn. The company is led by founder and CEO Sean McClain.

Absci Corp. specializes in an integrated AI Drug Creation Platform that focuses on biologics, particularly differentiated antibodies for conditions such as androgenetic alopecia. Their core product, ABS-201, targets prolactin receptors to stimulate hair follicle regeneration, promoting durable hair regrowth, as validated by in vivo studies. This platform employs a novel methodology that combines AI-driven drug discovery with wet lab validation.

Absci's products primarily serve pharmaceutical companies and clinical researchers seeking efficient therapeutic development and are especially relevant in North America and select regions in Europe. Absci Corp. 's revenue model is based on partnerships within the pharmaceutical and biotechnology sectors. They leverage collaborations for drug development and optimization, primarily through B2B agreements.

Clients contract Absci to utilize its AI Drug Creation Platform for specific biologics, including milestone payments tied to various drug development stages. The company's revenue for the most recent year, 2025, was USD 2. 80 mn, with an EBITDA of USD -108. 58 mn.

Absci Corp. plans to utilize the USD 20. 00 mn raised in their recent PIPE funding round to support continued growth in research and development activities, and other strategic investments. They are focused on launching new products, including advancements to ABS-201, targeting expanded indications and therapeutic areas.

The company aims to enter new geographic markets, particularly in Europe and Asia, by 2023, aligning with their strategy to capitalize on the growing demand for advanced biologic therapies.